Clinical trial
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic…
NCT00400816 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00400816 |
|---|---|
| Title | Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma |
| Official title | Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Central Nervous System Tumors, Brain Tumor |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 29 |
| Start date | Aug 1, 2005 |
| Primary completion | Jan 17, 2008 |
| Completion | Jan 6, 2016 |
| First posted | Nov 17, 2006 |
| Last update posted | Sep 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: